Grunenthal Logo

External Link

You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.

Gabriel Baertschi

Grünenthal acquires US-based Valinor Pharma

Grünenthal acquires the pharmaceutical company Valinor Pharma and becomes the global owner of Movantik® / Moventig® (naloxegol).

Movantik® is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik® in the United States reached over $200 million in 2023.

Grünenthal acquires US-based Valinor Pharma
As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio.
Gabriel BaertschiCEO, Grünenthal

Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.
Contact us

Grünenthal acquires US-based Valinor Pharma | Grünenthal